重大事件
外國發行人報告
6-K
2026-07-06
Radiopharm Theranostics獲澳洲政府589萬澳元研發退稅 支援放射性藥物開發
AI 繁中摘要
Radiopharm Theranostics（ASX: RAD, Nasdaq: RADX）今日宣佈，已收到澳洲政府 2025 財政年度嘅研發稅務退稅，總額為 589 萬澳元（連同 10.4 萬澳元利息）。呢筆資金係透過澳洲 R&D 稅務優惠計劃獲得，合資格公司可獲最高 43.5% 嘅可退還稅務抵免。💰
公司表示，呢筆退稅將為旗下診斷及治療用放射性藥物產品組合嘅持續開發提供重要資金。Radiopharm 係臨床階段嘅生物製藥公司，專注腫瘤放射性藥物，目前有一個 Phase 2 及五個 Phase 1 臨床試驗，針對肺癌、乳腺癌、腦癌等多種實體瘤。
今次 6-K 申報主要係披露呢項非經常性現金流入，對公司短期現金流有正面作用，有助支持現有研發進度。管理層未有提供具體展望指引，但強調資金將用於推進管線。投資者應留意呢筆退稅屬一次性政府補貼，並非經常性收入。 📊
展開英文正文
EX-99.1 2 ea029703401ex99-1.htm RADIOPHARM RECEIVES $5.9M R&D TAX INCENTIVE Exhibit 99.1 ASX ANNOUNCEMENT 3 July 2026 Radiopharm Receives $5.9M R&D Tax Incentive Sydney, Australia – 3 July 2026 – Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has received its research and development (R&D) tax refund for the 2025 financial year, totalling A$.5,885,131, including A$104,475 interest. The refund is received as part of the Australian Government’s R&D tax incentive, which provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 43.5%. The refund received by Radiopharm will provide important funding for continued development of its portfolio of radiopharmaceutical products for diagnostic and therapeutic applications. About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at radiopharmtheranostics.com. Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. For more information: Investors: Riccardo Canevari CEO & Managing Director P: +1 862 309 0293 E: [email protected] Anne Marie Fields Precision AQ (formerly Stern IR) E: [email protected] Paul Hopper Executive Chairman P: +61 406 671 515 E: [email protected] Radiopharm Theranostics Limited Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia ABN: 57 647 877 889 ASX ANNOUNCEMENT 3 July 2026 Media Matt Wright NWR Communications P: +61 451 896 420 E: [email protected] Follow Radiopharm Theranostics: Website – https://radiopharmtheranostics.com/ X – https://x.com/TeamRadiopharm LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/ InvestorHub – https://investorhub.radiopharmtheranostics.com/ Radiopharm Theranostics Limited Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia ABN: 57 647 877 889